AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

Struggling to control high BP? Learn about resistant hypertension, its causes, and expert-approved ways to manage it. Get ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients with uncontrolled or treatment-resistant hypertension, AstraZeneca ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Baxdrostat is an investigational highly selective, oral, small molecule designed to inhibit aldosterone synthase.

In addition to taking medication, paying attention to these habits can help maintain healthy blood pressure levels..resistant ...

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...